>
>
Peptide and Oligonucleotide CDMO Market Size – By Product (Peptide, Oligonucleotides), Service Type (Contract Manufacturing, Contract Development), Application (Therapeutics, Diagnostics, Research), End-use (Pharmaceutical, Biopharmaceutical) – Global Forecast (2024 – 2032)
Download Free PDF

Peptide and Oligonucleotide CDMO Market
Get a free sample of this reportGet a free sample of this report Peptide and Oligonucleotide CDMO Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 10
Tables & Figures: 237
Countries covered: 19
Pages: 135
Download Free PDF
Peptide and Oligonucleotide CDMO Market Size
Peptide and Oligonucleotide CDMO Market was valued at USD 2.3 billion in 2023 and is expected to register at a CAGR of over 12.1% from 2024 to 2032, due to the increasing demand for personalized medicine and targeted therapies, which require customized peptides and oligonucleotides. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and genetic disorders has led to a growing need for innovative therapeutic solutions, further fuelling the demand for peptide and oligonucleotide CDMO services.
Furthermore, advancements in biotechnology and the pharmaceutical industry have led to the development of more complex and potent peptides and oligonucleotides, creating opportunities for CDMOs to provide specialized manufacturing expertise. The expanding applications of peptides and oligonucleotides in areas such as diagnostics, drug delivery, and therapeutics are further driving the growth of the market.
Peptide and Oligonucleotide CDMO Market Trends
Peptide and Oligonucleotide CDMO Market Analysis
Based on the product, the market is classified into peptide and oligonucleotides. Peptide dominated the market with revenue of USD 1.5 billion in 2023.
Based on service type, the peptide and oligonucleotide CDMO market is segmented into contract manufacturing and contract development. The contract manufacturing segment held a dominant market share of 65.2% in 2023.
Based on application, the peptide and oligonucleotide CDMO market is classified into therapeutics, diagnostics, and research. The therapeutics segment is expected to reach USD 3.3 billion by 2032.
Based on end-use, the peptide and oligonucleotide CDMO market is classified into pharmaceutical companies, biopharmaceutical companies, and other end-users. The pharmaceutical companies segment dominated the market in 2023 and is anticipated to grow at a CAGR of over 12% through 2032.
In 2023, North America region captured about 44.9% share of global peptide and oligonucleotide CDMO market and is expected to reach USD 2.8 billion by 2032.
Peptide and Oligonucleotide CDMO Market Share
The competitive landscape of the peptide and oligonucleotide CDMO industry is characterized by the presence of established pharmaceutical companies vying for market share. Key market players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion, research and development, service diversification, and regulatory compliance to maintain a competitive edge in the market.
Peptide and Oligonucleotide CDMO Market Companies
Prominent players operating in the peptide and oligonucleotide CDMO industry are as mentioned below:
Peptide and Oligonucleotide CDMO Industry News
This peptide and oligonucleotide CDMO market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Product
Market, By Service Type
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: